Yes, viruses can trigger diabetes, and the evidence is strong for both Type 1 and Type 2. Several specific viruses have been linked to new diabetes diagnoses, though the relationship is rarely as simple as “catch a virus, get diabetes.” In most cases, a viral infection acts as a trigger in people who are already genetically susceptible, setting off an immune response that damages the pancreas or disrupts how the body processes sugar.
The Strongest Link: Enteroviruses and Type 1 Diabetes
The virus family most closely tied to Type 1 diabetes is the enterovirus group, particularly a subset called coxsackievirus B (CVB). These common viruses spread through contaminated water, food, or close contact and often cause mild cold-like or gastrointestinal symptoms. But in genetically susceptible people, they appear to trigger the immune attack on insulin-producing cells that defines Type 1 diabetes.
Two large meta-analyses, involving 4,448 and 5,921 participants respectively, have confirmed a statistically significant association between markers of enterovirus infection and the development of Type 1 diabetes. When researchers have examined pancreatic tissue from people recently diagnosed with Type 1 diabetes, about 16% of those who still had some functioning insulin-producing cells tested positive for enterovirus genetic material. Over 90% of those viral samples belonged to the enterovirus B species. Enteroviruses are now considered the single most implicated environmental factor in the onset and progression of Type 1 diabetes.
How a Virus Turns the Immune System Against Itself
There are three main ways a virus can lead the body’s immune system to destroy its own insulin-producing beta cells in the pancreas.
The first, and most studied, is called molecular mimicry. Some viruses carry surface structures that closely resemble proteins on beta cells. When the immune system mounts an attack against the virus, it also recognizes and attacks the look-alike cells in the pancreas. The immune system essentially can’t tell the difference between the invader and its own tissue.
The second is bystander activation. Here, the virus doesn’t need to look like a beta cell at all. Instead, the infection creates a storm of inflammatory signals near the pancreas. These signals can wake up immune cells that were previously ignoring beta cells, pulling them into an escalating cycle of inflammation and destruction. Immune cells not originally targeting the pancreas get drawn in by the local chemical environment and contribute to the damage.
The third mechanism is direct infection of beta cells. Several viruses, including enteroviruses, can infect beta cells directly and kill them. However, evidence from pancreatic tissue samples of newly diagnosed patients suggests this isn’t the most common pathway. Widespread beta cell death from direct viral attack is rare. The exception may be “fulminant diabetes,” an unusually rapid form of Type 1 diabetes where patients typically show signs of active infection at diagnosis.
Genetics Determine Who Is Vulnerable
Not everyone who catches an enterovirus develops diabetes. The difference largely comes down to a set of immune system genes called HLA genes, specifically HLA-DQB1, HLA-DQA1, and HLA-DRB1. These genes control how your immune system identifies threats, and certain variants make it far more likely that a viral infection will spark an autoimmune response against the pancreas.
People carrying both the DR3 and DR4 gene variants are in the highest risk group. More than 97% of people in this category also carry a specific gene variant (DQB1*0302) linked to the DR4 risk group. In these individuals, the cellular machinery responsible for processing and presenting viral proteins to the immune system is wired in a way that makes cross-reactive attacks on beta cells more likely. People carrying the DR3 variant, meanwhile, show heightened activity in stress response and inflammatory pathways, which may amplify the immune damage once it begins.
Rubella: A Historical Case Study
One of the clearest demonstrations of a virus causing diabetes comes from rubella. Children born with congenital rubella syndrome, meaning they were infected in the womb, develop diabetes at dramatically elevated rates. In a New York cohort of 242 children with congenital rubella, 12.4% developed diabetes by age 17. Given the normal background rate of about 22 cases per 100,000 children per year, only one child in that group would have been expected to develop Type 1 diabetes. Thirty actually did. By age 60, roughly 22% of people with congenital rubella syndrome had developed diabetes. Widespread rubella vaccination has made this particular pathway rare in developed countries, but it remains a powerful example of how viral exposure can permanently alter metabolic health.
Hepatitis C and Type 2 Diabetes
The virus-diabetes connection isn’t limited to Type 1. Chronic hepatitis C infection significantly increases the risk of Type 2 diabetes, and the mechanism is entirely different from the autoimmune pathways involved in Type 1. Rather than destroying insulin-producing cells, the hepatitis C virus interferes with how liver and muscle cells respond to insulin.
The virus disrupts insulin signaling at multiple points. It ramps up production of inflammatory molecules that block insulin’s normal effects on cells. It promotes the liver’s production of glucose even when blood sugar is already elevated. And it reduces the number of glucose transporters on cell surfaces, meaning cells absorb less sugar from the bloodstream. The combined effect is insulin resistance: the pancreas produces insulin, but the body can’t use it effectively. Epidemiological studies consistently show that people with chronic hepatitis C have significantly higher rates of Type 2 diabetes compared to people with hepatitis B, pointing to a direct role for the virus beyond general liver inflammation.
COVID-19 and New Diabetes Diagnoses
SARS-CoV-2, the virus behind COVID-19, has added a new chapter to this story. A systematic review and meta-analysis of 12 cohort studies involving more than 48 million participants found that the risk of developing new-onset diabetes was 41% higher in people who had COVID-19 compared to those who hadn’t been infected. This elevated risk appears to involve both Type 1 and Type 2 pathways. The virus that causes COVID-19 can directly infect beta cells, and the intense inflammatory response it triggers may also drive insulin resistance that persists long after the acute infection resolves.
Research on other infections supports the idea that even temporary illness can have lasting metabolic effects. Studies using precise insulin sensitivity testing have shown that insulin resistance increases during respiratory and gastrointestinal infections and can persist for more than three months afterward. In animal studies, this post-infection insulin resistance was temporary in lean subjects but became permanent in those that were already overweight, suggesting that pre-existing metabolic stress makes virus-triggered diabetes more likely to stick.
Evidence From Long-Term Childhood Studies
The TEDDY study, one of the largest prospective studies of childhood diabetes risk, followed thousands of genetically at-risk children from birth. It found that common respiratory infections reported by parents were associated with an increased risk of developing the autoantibodies that precede Type 1 diabetes. Gastrointestinal infections had a more complex relationship: depending on the child’s age at infection, they either increased or decreased the risk of autoimmunity. Norovirus, detected in stool samples, was specifically linked to the development of insulin-targeting autoantibodies in young children. The study also confirmed that enterovirus infection and gastroenteritis support different autoimmune pathways depending on whether the first autoantibody targets insulin (typically appearing between ages 1 and 3) or another beta cell protein called GAD65 (appearing at age 3 or older).
Vaccines as a Protective Strategy
If viruses can cause diabetes, preventing those infections should lower diabetes rates. There’s growing evidence this is true. A meta-analysis of five studies covering more than 4.4 million children in developed countries found that rotavirus vaccination was associated with a 13% lower risk of Type 1 diabetes compared to unvaccinated children. An earlier, larger meta-analysis of nearly 5.8 million children did not find a statistically significant effect, so the evidence is still being refined, but the trend is consistent.
Researchers are also developing vaccines specifically targeting the enteroviruses most strongly linked to Type 1 diabetes. A vaccine against coxsackievirus B1 has already shown the ability to prevent virus-induced diabetes in animal models. A broader vaccine covering all six coxsackievirus B types has demonstrated a strong safety profile and robust immune responses in both mice and primates. If successful in human trials, these vaccines could become the first direct prevention strategy for virus-triggered Type 1 diabetes.